Completed
NA
INTERVENTIONAL
NCT03082885
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.
Detailed Description
Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. In this study, the investigators intend to assess the efficacy and safety of Thymosin-α1 in patients with HBV-related Acute-on-chronic liver failure.
Interventions
Name:
Thymosin-α1
Type:
DRUG
Description:
1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
Primary Outcomes
Measure:
The liver transplantation-free survival rate of 90 days
TimeFrame:
90 days
Description:
Survival condition of the patients were observed for 90 days
Trial Information
NCT ID
NCT03082885
Status
Completed
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Sun Yat-sen University
Last Updated
December 15, 2025